Juan Jaen Sells 6,431 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 6,431 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $29.66, for a total value of $190,743.46. Following the completion of the sale, the president directly owned 890,809 shares of the company’s stock, valued at $26,421,394.94. The trade was a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Arcus Biosciences Stock Up 4.9%

Shares of NYSE RCUS opened at $30.22 on Friday. The business has a 50-day moving average price of $24.67 and a 200 day moving average price of $22.95. The stock has a market cap of $3.80 billion, a PE ratio of -9.50 and a beta of 0.85. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19. Arcus Biosciences, Inc. has a 52-week low of $7.91 and a 52-week high of $31.44.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The firm had revenue of $17.00 million for the quarter, compared to analyst estimates of $29.48 million. During the same period last year, the firm earned ($1.14) EPS. The company’s quarterly revenue was down 39.3% on a year-over-year basis. Equities research analysts forecast that Arcus Biosciences, Inc. will post -3.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

RCUS has been the topic of a number of recent research reports. Wedbush lifted their target price on shares of Arcus Biosciences from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of Arcus Biosciences in a research report on Monday, March 2nd. Morgan Stanley upped their target price on shares of Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Monday, May 11th. Finally, Lifesci Capital assumed coverage on shares of Arcus Biosciences in a research note on Thursday, June 4th. They set an “outperform” rating and a $46.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $35.10.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Hantz Financial Services Inc. raised its stake in shares of Arcus Biosciences by 121.9% during the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after purchasing an additional 881 shares during the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in Arcus Biosciences in the 4th quarter valued at $39,000. KBC Group NV purchased a new position in Arcus Biosciences in the 1st quarter valued at $50,000. GAMMA Investing LLC increased its stake in Arcus Biosciences by 17.5% in the 4th quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock valued at $77,000 after buying an additional 482 shares during the period. Finally, Royal Bank of Canada increased its stake in Arcus Biosciences by 14.6% in the 1st quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock valued at $102,000 after buying an additional 607 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.